Dubois T, Bisagni-Faure A, Coste J, Mavoungou E, Menkes C J, Russo-Marie F, Rothhut B
Laboratoire de Signalisation, Inflammation et Transformation Cellulaire, INSERM U.332, Institut Cochin de Génétique Moléculaire (ICGM), Université René Descartes, Paris, France.
J Rheumatol. 1995 Jul;22(7):1230-4.
Glucocorticoids are powerful antiinflammatory agents widely used for the treatment of rheumatoid arthritis (RA). Synthesis and/or secretion of annexin I (A-I) is induced by these steroids. Annexins V and VI are also found extracellularly but are not induced by glucocorticoids. Annexins may be potent antagonists of phospholipase A2 (PLA2). Since autoantibodies to A-I have been reported in patients with RA, we studied the reactivity of sera from patients with RA to A-V and A-VI.
Sera from 26 patients with RA were assessed for anti-A-V and anti-A-VI antibodies and compared with sera from 26 sex/age matched healthy subjects. IgG and IgM antibodies were analyzed in an ELISA: A correlation study with disease activity and corticosteroid treatment schedule was performed.
Sera from patients with RA contained significantly higher levels of IgG [anti-A-V and anti-A-VI] autoantibodies than control sera, both being correlated. This rise in antiannexin antibody titers was correlated with the RA activity score, and negatively correlated with the daily dose of corticosteroids.
High levels of IgG (anti-A-V and anti-A-VI) antibodies were found in sera from patients with RA. We suggest that antiannexin autoantibodies may play a role in the clinical course of RA by impairing the anti-PLA2 effect of annexins.
糖皮质激素是广泛用于治疗类风湿关节炎（RA）的强效抗炎药。这些类固醇可诱导膜联蛋白I（A-I）的合成和/或分泌。膜联蛋白V和VI也存在于细胞外，但不受糖皮质激素诱导。膜联蛋白可能是磷脂酶A2（PLA2）的有效拮抗剂。由于在RA患者中已报道了针对A-I的自身抗体，我们研究了RA患者血清对A-V和A-VI的反应性。
评估26例RA患者血清中的抗A-V和抗A-VI抗体，并与26例性别/年龄匹配的健康受试者的血清进行比较。通过酶联免疫吸附测定（ELISA）分析IgG和IgM抗体：进行了疾病活动与皮质类固醇治疗方案的相关性研究。
RA患者血清中IgG [抗A-V和抗A-VI]自身抗体水平明显高于对照血清，两者相关。抗膜联蛋白抗体滴度的升高与RA活动评分相关，与皮质类固醇的每日剂量呈负相关。
在RA患者血清中发现高水平的IgG（抗A-V和抗A-VI）抗体。我们认为抗膜联蛋白自身抗体可能通过损害膜联蛋白的抗PLA2作用而在RA的临床病程中发挥作用。
